Abstract
A pretargeted imaging strategy based on the HaloTag dehalogenase enzyme is described. Here, a HaloTag-Trastuzumab conjugate has been used as the primary agent targeting HER2 expression, and three new radiolabelled HaloTag ligands have been used as secondary agents, two of which offer dual-modality (SPECT/optical) imaging capability.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antibodies, Monoclonal, Humanized / metabolism*
-
Cell Line, Tumor
-
Halogens / metabolism*
-
Humans
-
Hydrolases / metabolism*
-
Ligands
-
Optical Imaging / methods*
-
Tomography, Emission-Computed, Single-Photon / methods*
-
Trastuzumab
Substances
-
Antibodies, Monoclonal, Humanized
-
Halogens
-
Ligands
-
Hydrolases
-
Trastuzumab